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Abstract: CD146 has been regarded as a novel potential therapeutic target for multiple 
cancers. The aim of the study was to investigate the expression of CD146 in gastric cancer 
and  evaluate  its  clinical-pathological  and  prognostic  significance.  The  expression  of 
CD146 and three epithelial-mesenchymal transition (EMT)-related proteins (E-cadherin,  
β-catenin and vimentin) was examined in 144 gastric cancers by immunohistochemistry. 
Fifty-nine cases (41.0%) were defined as positive for CD146 expression. We found that 
CD146  expression  correlated  positively  with  lymph  node  involvement  and  a  poor 
prognosis,  and  retained  an  independent  prognostic  factor  for  gastric  cancer  patients. 
Furthermore,  positive  expression  of  CD146  was  strongly  associated  with  loss  of  the 
epithelial marker E-cadherin and acquisition of the expression of the mesenchymal markers 
nuclear β-catenin and vimentin. These findings suggest that CD146 might promote EMT 
and progression in gastric cancer, and thus may be a potential therapeutic target for patients 
with gastric cancers. 
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1. Introduction 
Gastric cancer is one of the most frequent cancers worldwide. In China, gastric cancer ranks the 
third most common cancer [1]. Although the establishment of screening, early diagnosis and curative 
operation has increased survivals significantly, recurrence and metastasis remains a great challenge for 
patients with gastric cancer. In this context, there is an urgent need to find novel cancer-related factors 
to be used as biomarkers for diagnosis and therapeutic targets of gastric cancer.  
CD146, also known as MCAM, Mel-CAM, MUC18, S-endo1, was ﬁrst identiﬁed as a cell-adhesion 
molecule speciﬁc for melanoma [2]. CD146 plays a critical pro-migratory role in the vascular system, 
normal  development,  and  tumor  progression  patterning  [3,4].  Overexpression  of  CD146  has  been 
discovered in many cancers, including melanoma, prostate cancer, epithelial ovarian cancer, and breast 
cancer, and is associated with tumor progression [5–7]. The many underlying mechanisms of CD146 
involved  in  cancer  progression  are  now  being  elucidated.  The  epithelial  to  mesenchymal  
transition (EMT) is a mechanism by which tumor cells acquire characteristics which could increase 
their metastatic potential, and targeting EMT processes is therefore a promising strategy to block the 
transition to metastatic phenotype and improve the patients' outcome. A panel of EMT markers has 
been identified including up-regulation of mesenchymal vimentin, N-cadherin, and nuclear β-catenin, 
and down-regulation of epithelial markers E-cadherin. Most recently, Zeng et al. showed a striking 
association between CD146 and EMT in breast cancer [8]. Firstly, CD146 could induce EMT of the 
breast cancer cells via the activation of RhoA and up-regulation of the key EMT transcriptional factor 
Slug. Secondly, overexpression of CD146 was strongly associated with E-cadherin down-regulation in 
triple-negative breast cancers (TNBC) samples. Thus, CD146 could be an attractive target for cancer 
therapy and a potential biomarker for cancer prognosis.  
However, currently, no study has reported CD146 expression in gastric cancer patients. Therefore, 
in  the  present  study,  the  expression  of  CD146  in  gastric  cancer  and  its  association  with 
clinicopathological parameters and prognosis were evaluated. Furthermore, the association of CD146 
and three EMT markers (E-cadherin, β-catenin and vimentin) was also investigated. 
2. Results and Discussion 
2.1. Expression of CD146 and EMT Markers in Gastric Cancer 
Immunohistochemistry revealed that CD146 positive staining was localized in the membrane and 
cytoplasm of tumor cells in gastric cancer. According to the criteria established for immunostaining, 
41.0% (59/144) of tumors were positive for CD146 staining. To investigate whether the abnormally 
high expression of CD146 in gastric cancers accounts for its EMT-like features, we further analyzed 
correlations  between  CD146  and  three  EMT  markers.  In  gastric  cancers,  epithelial  protein  loss 
frequency  was  31.2%  (45⁄144)  for  E-cadherin,  and  aberrant  mesenchymal  protein  expression Int. J. Mol. Sci. 2012, 13  6401 
 
 
frequencies were 56.3% (81⁄144) for nuclear β-catenin and 56.3% (81⁄144) for vimentin. Figure 1 
shows the representative immunohistochemistry results. 
Figure 1. Representative images showing cytoplasmic and membranous CD146 expression (A); 
E-cadherin loss (B); cytoplasmic vimentin expression (C); and nuclear β-catenin expression 
(D) in gastric cancers (× 200 magnitude). 
 
2.2. Correlation between CD146 Expression with Clinicopathological Characteristics and EMT 
Markers in Gastric Cancer 
The  correlation  between  CD146  expression  status  and  the  clinicopathological  characteristics  in 
gastric cancer was further analyzed and the results are summarized in Table 1. Over-expression of 
CD146 was closely related to lymph node metastasis (P < 0.001), but no signiﬁcant correlation was 
present with patients’ age, gender, the depth of invasion, pTNM stage and histology. Moreover, the 
positive expression of CD146 was negatively correlated with E-cadherin (r = −0.185, P = 0.032) and 
was  positively  associated  with  nuclear  β-catenin  (r  =  0.41,  P  <  0.001)  and  vimentin  (r  =  0.287,  
P = 0.001) expression (Table 2). 
Table 1. Correlations between CD146 with clinicopathologic characteristics. 
Clinical Factors  n 
CD146 
Negative 
(n = 75) 
Positive  
(n = 59) 
P Value 
Age (year)         
<65  96  54  42  0.917 
≥65  38  21  17   Int. J. Mol. Sci. 2012, 13  6402 
 
 
Table 1. Cont. 
Gender         
Male  90  52  38  0.547 
Female  44  23  21   
Depth         
T1/T2  27  16  11  0.700 
T3/T4   107  59  48   
Nodal involvement         
Yes  93  42  51  <0.001 
No  41  33  8   
pTNM stage         
1/2  44  23  21  0.547 
3/4  90  52  38   
Histology         
Differentiated   75  46  29  0.159 
Undifferentiated   59  29  30   
Table 2. Correlations between CD146 with EMT markers. 
EMT Markers  n 
CD146 
Negative  Positive   r  P Value 
Ecadherin           
Negative  89  44  45  −0.185  0.032 
Positive  45  31  14     
Nuclear β-catenin           
Negative  53  43  10  0.41  <0.001 
Positive  81  32  49     
Vimentin           
Negative  53  39  14  0.287  0.001 
Positive  81  36  45     
2.3. Correlation between CD146 and EMT Markers Expression with Gastric Cancer Survival  
Patients with positive CD146 expression showed a more unfavorable prognosis than those with no 
expression (Figure 2A). This was also true for increased expression of vimentin and nuclear β-catenin 
(Figure 2C,D). However the absence of E-cadherin was associated with no significant difference in 
outcomes (Figure 2B). Moreover, as seen in Table 3, multivariate Cox analysis showed that CD146 
over-expression was an independent prognostic factor for patients with gastric cancer (P = 0.027). 
Table 3. Multivariate analysis with regard to overall survival. 
Parameter 
Multivariate Analysis 
p-Value  RR (95% CI) 
Age (<65 vs. ≥65)  0.332  1.257 (0.792–1.996) 
Gender (male vs. female)  0.579  1.137 (0.722–1.792) 
Depth (T1/T2 vs. T3/T4)  0.105  0.560 (0.278–1.128) 
Lymph node metastasis (yes vs. no)  0.001  3.256 (1.595–6.647) Int. J. Mol. Sci. 2012, 13  6403 
 
 
Table 3. Cont. 
Histology (differentiated vs. undifferentiated)  0.862  1.038 (0.685–1.572) 
pTNM stage (3/4 vs. 1/2)  0.141  1.442 (0.886–2.344) 
E-cadherin (Positive vs. negative)  0.715  1.086 (0.697–1.693) 
Nuclear β-catenin (positive vs. negative)  0.002  2.096 (1.312–3.347) 
Vimentin (positive vs. negative)  0.037  1.664 (1.031–2.686) 
CD146 (positive vs. negative)  0.027  1.744 (1.066–2.853) 
Figure  2.  Overall  survival  curves  of  patients  with  gastric  cancer  according  to  the 
immunostaining  results  of  CD146  (A);  loss  of  E-cadherin  (B);  aberrant  expression  of 
vimentin (C); and β-catenin (D); determined by the Kaplan–Meier analysis. 
 
2.4. Discussion 
CD146, a cell-cell or cell-matrix adhesion molecule, was first described in melanomas. Although, a 
few studies have indicated its role as a tumor suppressor [9], accumulating evidence supports that 
CD146 acts as a pro-metastatic factor [10]. In particular, many recent studies have identified that the 
high expression of CD146 has been associated with metastatic progression in prostate cancer, breast 
cancer  and  ovarian  cancer.  A  critical  question  raised  was  whether  CD146  expression  clinically Int. J. Mol. Sci. 2012, 13  6404 
 
 
correlated with gastric cancer progression. To address this issue, we performed immunohistochemistry 
to detect CD146 expression in 144 human primary gastric cancers. 
In  this  study,  our  data  demonstrated  that  a  subset  (41.0%)  of  human  primary  gastric  cancers 
expressed CD146 proteins in the epithelial compartment. CD146 expression correlated with lymph 
node metastasis status, and was associated with a poor overall survival. Cox model analysis revealed 
that CD146 was  an independent  prognostic factor for  gastric patients.  Our  findings  indicated that 
similar to other solid cancers recently investigated, CD146 was also associated with tumor metastasis 
and poor prognosis in gastric cancer, and further enhanced the role of CD146 in the progression of cancers.  
In  vitro  assays  revealed  that  CD146  silencing  in  cancer  cells  resulted  in  down-regulation  of 
mesenchymal  markers  (vimentin  and  ﬁbronectin)  and  up-regulation  of  the  epithelial  marker  
(E-cadherin) [7,8]. Consistent with such changes in EMT markers, functional assays revealed that 
CD146 silencing was also accompanied by decreased migration and invasion abilities of cancer cells. 
Zeng et al. [8] suggests that RhoA pathway-mediated EMT transcriptional factor Slug activation could 
be  a  key  mechanism  for  the  EMT  induced  by  CD146  in  cancer  cells.  Moreover,  Zeng  et  al.  [8] 
demonstrated the correlation between CD146 expression and E-cadherin down-regulation in breast 
cancers. Established drivers of EMT include activated transforming growth factor b (aTGFb), Snail or 
Zeb1 [11]. In this study, using three EMT markers, we further confirmed that CD146 over-expression 
was associated not only with E-cadherin down-regulation, but also with acquisition of the expression 
of the mesenchymal markers nuclear β-catenin and vimentin. Our data further indicated that CD146 
was strongly associated with EMT protein changes in clinical cancer samples. 
Previous studies have confirmed that EMT is associated with the progressive phenotypes and poor 
outcome in gastric cancer [12,13]. Considering that CD146 is closely related to EMT and progression 
of gastric cancer, we suggest that CD146 inhibition might offer a promising target for EMT reversion 
and prevention of metastatic progression and invasion in gastric cancer. 
3. Experimental Section 
3.1. Patients 
A  total  of  144  patients  with  histologically  confirmed  gastric  adenocarcinoma  invading  the 
submucosal  layer  or  deeper  were  retrospectively  included  in  this  study.  All  patients  received  the 
curative gastrectomy with lymph node dissection at Tongji Hospital of Tongji University, Shanghai, 
China  between  January  2006  and  September  2009.  All  the  patients  received  postoperative 
chemotherapy  regimen  based  on  5-fluorouracil  plus  leucovorin.  No  patient  received  preoperative 
chemotherapy and/or radiotherapy. The clinicopathological characteristics of the patients, including 
age, gender, pathological TNM stage (pTNM stage), histology, depth, and lymph node metastasis 
status, are seen in Table 1. Follow-up information, including patient outcome and the time interval 
between the date of surgical resection and the date of the cancer-related death, was collected. Those 
cases lost to follow-up and deaths from causes other than gastric cancer were regarded as censored 
data for the analysis of survival. The study was approved by our local ethics committees. Specimens 
were obtained with informed consent. Int. J. Mol. Sci. 2012, 13  6405 
 
 
3.2. Immunohistochemistry 
Immunohistochemistry was performed to detect the expression of CD146, E-cadherin, β-catenin 
and  vimentin  in  formalin-ﬁxed  parafﬁn-embedded  gastric  cancer  specimens.  Briefly,  4  µm  thick 
sections  were  deparaffinized  with  xylene,  then  were  incubated  with  0.3%  hydrogen  peroxide  
for 30 min to block the endogenous peroxidases. After treatment with normal goat serum for 1 h to 
block  nonspeciﬁc  binding,  primary  antibodies  against  CD146  (Abcam,  1:100,  Cat.  #  ab75769),  
E-cadherin (Santa Cruz, 1:200, Cat. # sc-8426), β-catenin (Santa Cruz, 1:100, Cat. # sc-7199) and 
vimentin (Santz Cruz, 1:100, Cat.  # sc-32322)  were added, respectively. Primary antibodies  were 
detected using a HRP Envision System kit (Dako, Gene Co. Ltd., Shanghai, China), and then were 
counterstained with hematoxylin. For the negative controls, the primary antibodies were replaced by 
mouse or rabbit IgG (Santa Cruz). 
The results of immunostaining were evaluated based upon the percentage of mild or strong staining 
cancer cells to the total cancer cells. According to the criteria established in the previous studies, 
immunohistochemistry results were considered to be positive when the percentage of mild staining cells 
was greater than >10% of tumor cells. β-catenin nuclear localization was considered aberrant expression.  
3.3. Statistical Analysis 
The relationship between CD146 expression and clinicopathologic variables was evaluated using 
Chi-square test. The nonparametric Spearman rank correlation coefﬁcient was applied to analyze the 
relationship between CD146 and EMT markers. Overall survival of patients was estimated by the 
Kaplan-Meier method, and the statistical signiﬁcance of the differences were compared by the log-rank 
test. A Cox proportional hazards regression model was used for the multivariate analysis. All the 
statistical analyses were performed with SPSS 16.0 (SPSS: Chicago, IL, USA, 2008). P ≤ 0.05 was 
considered statistically significant. 
4. Conclusions  
In conclusion, we found that CD146 was associated with lymph node metastasis and EMT marker 
changes in gastric cancer, and was also a novel prognostic factor. The findings are consistent with the 
expression of CD146 in other cancers such as breast cancer. We suggest that CD146 could be also 
used as a potential therapeutic target for patients with gastric cancers. 
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